Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pulmatrix stock | 1.1

Own Pulmatrix stock in just a few minutes.

Posted

Fact checked

Pulmatrix, Inc is a biotechnology business based in the US. Pulmatrix shares (PULM) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmatrix employs 22 staff and has a trailing 12-month revenue of around USD$9.4 million.

How to buy shares in Pulmatrix

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pulmatrix. Find the stock by name or ticker symbol: PULM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pulmatrix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.1, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pulmatrix, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pulmatrix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pulmatrix share price

Use our graph to track the performance of PULM stocks over time.

Pulmatrix shares at a glance

Information last updated 2020-10-14.
Latest market close USD$1.1
52-week range USD$0.6103 - USD$2.055
50-day moving average USD$1.1361
200-day moving average USD$1.4047
Wall St. target price USD$10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.467

Buy Pulmatrix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pulmatrix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pulmatrix price performance over time

Historical closes compared with the close of $1.1 from 2020-11-16

1 week (2020-11-16) 1.1
1 month (2020-10-23) -2.65%
3 months (2020-08-24) -6.78%
6 months (2020-05-22) -41.49%
1 year (2019-11-22) 35.80%
2 years (2018-11-23) 182.34%
3 years (2017-11-24) -32.52%
5 years (2015-11-24) -77.80%

Pulmatrix financials

Revenue TTM USD$9.4 million
Gross profit TTM USD$-4,935,000
Return on assets TTM -23.74%
Return on equity TTM -84.14%
Profit margin -143.83%
Book value $0.539
Market capitalisation USD$40.6 million

TTM: trailing 12 months

Shorting Pulmatrix shares

There are currently 118,321 Pulmatrix shares held short by investors – that's known as Pulmatrix's "short interest". This figure is 20.9% up from 97,855 last month.

There are a few different ways that this level of interest in shorting Pulmatrix shares can be evaluated.

Pulmatrix's "short interest ratio" (SIR)

Pulmatrix's "short interest ratio" (SIR) is the quantity of Pulmatrix shares currently shorted divided by the average quantity of Pulmatrix shares traded daily (recently around 455080.76923077). Pulmatrix's SIR currently stands at 0.26. In other words for every 100,000 Pulmatrix shares traded daily on the market, roughly 260 shares are currently held short.

However Pulmatrix's short interest can also be evaluated against the total number of Pulmatrix shares, or, against the total number of tradable Pulmatrix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pulmatrix's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pulmatrix shares in existence, roughly 0 shares are currently held short) or 0.0035% of the tradable shares (for every 100,000 tradable Pulmatrix shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pulmatrix.

Find out more about how you can short Pulmatrix stock.

Pulmatrix share dividends

We're not expecting Pulmatrix to pay a dividend over the next 12 months.

Have Pulmatrix's shares ever split?

Pulmatrix's shares were split on a 1:10 basis on 6 February 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pulmatrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pulmatrix shares which in turn could have impacted Pulmatrix's share price.

Pulmatrix share price volatility

Over the last 12 months, Pulmatrix's shares have ranged in value from as little as $0.6103 up to $2.055. A popular way to gauge a stock's volatility is its "beta".

PULM.US volatility(beta: 1.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmatrix's is 1.417. This would suggest that Pulmatrix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pulmatrix overview

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site